206 related articles for article (PubMed ID: 27093208)
1. [The extra-glycemic effects of liraglutide: focus on cardiometabolic markers].
Giglio RV; Patti AM; Nikolic D; Castellino G; Noto M; Parrino A; Montalto G; Rizzo M
G Ital Cardiol (Rome); 2016 Apr; 17(4):253-8. PubMed ID: 27093208
[TBL] [Abstract][Full Text] [Related]
2. GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms.
Rizzo M; Nikolic D; Patti AM; Mannina C; Montalto G; McAdams BS; Rizvi AA; Cosentino F
Biochim Biophys Acta Mol Basis Dis; 2018 Sep; 1864(9 Pt B):2814-2821. PubMed ID: 29778663
[TBL] [Abstract][Full Text] [Related]
3. Liraglutide Improves Glycemic and Blood Pressure Control and Ameliorates Progression of Left Ventricular Hypertrophy in Patients with Type 2 Diabetes Mellitus on Peritoneal Dialysis.
Hiramatsu T; Ozeki A; Asai K; Saka M; Hobo A; Furuta S
Ther Apher Dial; 2015 Dec; 19(6):598-605. PubMed ID: 26556397
[TBL] [Abstract][Full Text] [Related]
4. Fixed combination of insulin and a glucagon-like peptide-1 analog for the treatment of type 2 diabetes, exemplified by insulin degludec and liraglutide.
Vedtofte L; Knop FK; Vilsbøll T
Expert Rev Clin Pharmacol; 2015 May; 8(3):273-82. PubMed ID: 25816888
[TBL] [Abstract][Full Text] [Related]
5. Liraglutide for the prevention of major adverse cardiovascular events in diabetic patients.
Madsbad S
Expert Rev Cardiovasc Ther; 2019 May; 17(5):377-387. PubMed ID: 31055989
[No Abstract] [Full Text] [Related]
6. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
Wang B; Zhong J; Lin H; Zhao Z; Yan Z; He H; Ni Y; Liu D; Zhu Z
Diabetes Obes Metab; 2013 Aug; 15(8):737-49. PubMed ID: 23433305
[TBL] [Abstract][Full Text] [Related]
7. Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study.
Rizzo M; Rizvi AA; Patti AM; Nikolic D; Giglio RV; Castellino G; Li Volti G; Caprio M; Montalto G; Provenzano V; Genovese S; Ceriello A
Cardiovasc Diabetol; 2016 Dec; 15(1):162. PubMed ID: 27912784
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular safety of liraglutide for the treatment of type 2 diabetes.
Chudleigh RA; Bain S
Expert Opin Drug Saf; 2017 May; 16(5):627-635. PubMed ID: 28387138
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular safety and benefits of GLP-1 receptor agonists.
Dalsgaard NB; Brønden A; Vilsbøll T; Knop FK
Expert Opin Drug Saf; 2017 Mar; 16(3):351-363. PubMed ID: 28102093
[TBL] [Abstract][Full Text] [Related]
10. Is treatment with liraglutide efficient?
Mezquita Raya P; Reyes García R
Endocrinol Nutr; 2014 Apr; 61(4):202-8. PubMed ID: 24071060
[TBL] [Abstract][Full Text] [Related]
11. [Drug therapy of type 2 diabetes and cardiovascular prevention: potentials for liraglutide].
Reboldi G
G Ital Cardiol (Rome); 2009 Jul; 10(7):434-47. PubMed ID: 19761101
[TBL] [Abstract][Full Text] [Related]
12. Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial.
Hermansen K; Bækdal TA; Düring M; Pietraszek A; Mortensen LS; Jørgensen H; Flint A
Diabetes Obes Metab; 2013 Nov; 15(11):1040-8. PubMed ID: 23683069
[TBL] [Abstract][Full Text] [Related]
13. [Possibilities of influencing cardiovascular risk in type 2 diabetes mellitus by antidiabetic treatment Lowering of cardiovascular risk in treatment with liraglutide - Results of the LEADER].
Olšovský J
Vnitr Lek; 2016; 62(7-8):613-5. PubMed ID: 27627086
[TBL] [Abstract][Full Text] [Related]
14. [Tight glycemic control in the management of diabetic patients: what has changed since the '90s in the clinical approach?].
Fiorentino TV; Sesti G
G Ital Cardiol (Rome); 2014 Dec; 15(12 Suppl 2):13S-20S. PubMed ID: 25623546
[TBL] [Abstract][Full Text] [Related]
15. GLP-1 receptor agonists: effects on cardiovascular risk reduction.
Lorber D
Cardiovasc Ther; 2013 Aug; 31(4):238-49. PubMed ID: 23865382
[TBL] [Abstract][Full Text] [Related]
16. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.
Montanya E; Sesti G
Clin Ther; 2009 Nov; 31(11):2472-88. PubMed ID: 20109994
[TBL] [Abstract][Full Text] [Related]
17. A Comparison of the Effects of the GLP-1 Analogue Liraglutide and Insulin Glargine on Endothelial Function and Metabolic Parameters: A Randomized, Controlled Trial Sapporo Athero-Incretin Study 2 (SAIS2).
Nomoto H; Miyoshi H; Furumoto T; Oba K; Tsutsui H; Miyoshi A; Kondo T; Tsuchida K; Atsumi T; Manda N; Kurihara Y; Aoki S;
PLoS One; 2015; 10(8):e0135854. PubMed ID: 26284918
[TBL] [Abstract][Full Text] [Related]
18. Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents.
Blonde L; Montanya E
Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():20-32. PubMed ID: 22405266
[TBL] [Abstract][Full Text] [Related]
19. Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: A sub-analysis of a randomized, placebo-controlled, double-blind, crossover trial.
von Scholten BJ; Persson F; Rosenlund S; Eugen-Olsen J; Pielak T; Faber J; Hansen TW; Rossing P
Diabetes Obes Metab; 2017 Jun; 19(6):901-905. PubMed ID: 28105731
[TBL] [Abstract][Full Text] [Related]
20. Practice pearl: liraglutide and cardiovascular and renal events in type 2 diabetes.
Guthrie R
Postgrad Med; 2018 Mar; 130(2):154-158. PubMed ID: 29350569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
